378 related articles for article (PubMed ID: 28780145)
21. The shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia.
Jacobs RW; Awan FT; Leslie LA; Usmani SZ; Ghosh N
Expert Rev Hematol; 2016 Dec; 9(12):1177-1187. PubMed ID: 27791448
[TBL] [Abstract][Full Text] [Related]
22. Chronic lymphocytic leukemia therapy: new targeted therapies on the way.
Vitale C; Burger JA
Expert Opin Pharmacother; 2016 Jun; 17(8):1077-89. PubMed ID: 26988407
[TBL] [Abstract][Full Text] [Related]
23. Ibrutinib, obinutuzumab, idelalisib, and beyond: review of novel and evolving therapies for chronic lymphocytic leukemia.
Chung C; Lee R
Pharmacotherapy; 2014 Dec; 34(12):1298-316. PubMed ID: 25355689
[TBL] [Abstract][Full Text] [Related]
24. Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).
Odetola O; Ma S
Curr Hematol Malig Rep; 2023 Oct; 18(5):130-143. PubMed ID: 37278884
[TBL] [Abstract][Full Text] [Related]
25. Progress in the treatment of elderly/unfit chronic lymphocytic leukemia patients: results of the German CLL-11 trial.
Molica S
Expert Rev Anticancer Ther; 2015 Jan; 15(1):9-15. PubMed ID: 25479582
[TBL] [Abstract][Full Text] [Related]
26. Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia.
Del Poeta G; Postorino M; Pupo L; Del Principe MI; Dal Bo M; Bittolo T; Buccisano F; Mariotti B; Iannella E; Maurillo L; Venditti A; Gattei V; de Fabritiis P; Cantonetti M; Amadori S
Drugs Today (Barc); 2016 Apr; 52(4):249-60. PubMed ID: 27252989
[TBL] [Abstract][Full Text] [Related]
27. Sequencing of chronic lymphocytic leukemia therapies.
Barrientos JC
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):128-136. PubMed ID: 27913471
[TBL] [Abstract][Full Text] [Related]
28. Management of chronic lymphocytic leukemia.
Stilgenbauer S; Furman RR; Zent CS
Am Soc Clin Oncol Educ Book; 2015; ():164-75. PubMed ID: 25993154
[TBL] [Abstract][Full Text] [Related]
29. Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.
Barrientos JC
Future Oncol; 2016 Sep; 12(18):2077-94. PubMed ID: 27324214
[TBL] [Abstract][Full Text] [Related]
30. Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: Linking mechanisms with infections.
Hilal T; Gea-Banacloche JC; Leis JF
Blood Rev; 2018 Sep; 32(5):387-399. PubMed ID: 29571669
[TBL] [Abstract][Full Text] [Related]
31. Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia.
Abou Zahr A; Bose P; Keating MJ
Expert Opin Pharmacother; 2017 Jun; 18(9):857-873. PubMed ID: 28446054
[TBL] [Abstract][Full Text] [Related]
32. Combination of Targeted Drugs to Control Chronic Lymphocytic Leukemia: Harnessing the Power of New Monoclonal Antibodies in Combination With Ibrutinib.
Cramer P; Langerbeins P; Hallek M
Cancer J; 2016; 22(1):62-6. PubMed ID: 26841018
[TBL] [Abstract][Full Text] [Related]
33. Novel Therapies for Chronic Lymphocytic Leukemia: A Canadian Perspective.
Owen C; Assouline S; Kuruvilla J; Uchida C; Bellingham C; Sehn L
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):627-634.e5. PubMed ID: 26416145
[TBL] [Abstract][Full Text] [Related]
34. Initial treatment of CLL: integrating biology and functional status.
Jain N; O'Brien S
Blood; 2015 Jul; 126(4):463-70. PubMed ID: 26065656
[TBL] [Abstract][Full Text] [Related]
35. The Next Generation of Targeted Molecules for the Treatment of Chronic Lymphocytic Leukemia.
Jeyakumar D; O'Brien S
Oncology (Williston Park); 2016 Nov; 30(11):1008-15. PubMed ID: 27854102
[TBL] [Abstract][Full Text] [Related]
36. Approaches to Chronic Lymphocytic Leukemia Therapy in the Era of New Agents: The Conundrum of Many Options.
Jain N; Thompson P; Ferrajoli A; Nabhan C; Mato AR; O'Brien S
Am Soc Clin Oncol Educ Book; 2018 May; 38():580-591. PubMed ID: 30231393
[TBL] [Abstract][Full Text] [Related]
37. Outcomes of patients with chronic lymphocytic leukemia treated with first-line idelalisib plus rituximab after cessation of treatment for toxicity.
Thompson PA; Stingo F; Keating MJ; Ferrajoli A; Burger JA; Wierda WG; Kadia TM; O'Brien SM
Cancer; 2016 Aug; 122(16):2505-11. PubMed ID: 27182988
[TBL] [Abstract][Full Text] [Related]
38. The potential combination of BCL-2 inhibitors and ibrutinib as frontline therapy in chronic lymphocytic leukemia.
Aw A; Brown JR
Leuk Lymphoma; 2017 Oct; 58(10):2287-2297. PubMed ID: 28482721
[TBL] [Abstract][Full Text] [Related]
39. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.
Stilgenbauer S; Eichhorst B; Schetelig J; Coutre S; Seymour JF; Munir T; Puvvada SD; Wendtner CM; Roberts AW; Jurczak W; Mulligan SP; Böttcher S; Mobasher M; Zhu M; Desai M; Chyla B; Verdugo M; Enschede SH; Cerri E; Humerickhouse R; Gordon G; Hallek M; Wierda WG
Lancet Oncol; 2016 Jun; 17(6):768-778. PubMed ID: 27178240
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial.
Jones JA; Robak T; Brown JR; Awan FT; Badoux X; Coutre S; Loscertales J; Taylor K; Vandenberghe E; Wach M; Wagner-Johnston N; Ysebaert L; Dreiling L; Dubowy R; Xing G; Flinn IW; Owen C
Lancet Haematol; 2017 Mar; 4(3):e114-e126. PubMed ID: 28257752
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]